Проблемы гериатрии в кардиологической практике

Еще во второй половине XX века вместе с ростом продолжительности жизни было отмечено увеличение доли населения пожилого и старческого возраста. Однако, несмотря на увеличение ожидаемой продолжительности жизни, со старением возрастает распространенность большинства хронических заболеваний и функциональных нарушений. Пожилой и старческий возраст ассоциируется с риском развития сердечно-сосудистых заболеваний (ССЗ), в связи с чем проблема ведения пожилых пациентов с ССЗ становится особенно актуальной.

1. Ravindrarajah R, Hazra NC, Hamada S, Charlton J, Jackson SHD, Dregan A et al. Systolic Blood Pressure Trajectory, Frailty, and AllCause Mortality >80 Years of Age: Cohort Study Using Electronic Health Records. Circulation. 2017;135(24):2357–68. DOI: 10.1161/CIRCULATIONAHA.116.026687

2. Delgado J, Bowman K, Ble A, Masoli J, Han Y, Henley W et al. Blood Pressure Trajectories in the 20 Years Before Death. JAMA Internal Medicine. 2018;178(1):93–9. DOI: 10.1001/jamainternmed.2017.7023

3. Sergi G, Veronese N, Fontana L, De Rui M, Bolzetta F, Zambon S et al. Pre-Frailty and Risk of Cardiovascular Disease in Elderly Men and Women. Journal of the American College of Cardiology. 2015;65(10):976–83. DOI: 10.1016/j.jacc.2014.12.040

4. Бойцов С.А., Погосова Н.В., Бубнова М.Г., Драпкина О.М., Гаврилова Н.Е., Еганян Р.А. и др. Кардиоваскулярная профилактика 2017. Российские национальные рекомендации. Российский кардиологический журнал. 2018;23(6):7–122. DOI: 10.15829/1560-4071-2018-6-7-122

5. Sabayan B, Oleksik AM, Maier AB, van Buchem MA, Poortvliet RKE, de Ruijter W et al. High Blood Pressure and Resilience to Physical and Cognitive Decline in the Oldest Old: The Leiden 85-Plus Study. Journal of the American Geriatrics Society. 2012;60(11):2014–9. DOI: 10.1111/j.1532-5415.2012.04203.x

6. Ogliari G, Westendorp RGJ, Muller M, Mari D, Torresani E, Felicetta I et al. Blood pressure and 10-year mortality risk in the Milan Geriatrics 75+ Cohort Study: role of functional and cognitive status. Age and Ageing. 2015;44(6):932–7. DOI: 10.1093/ageing/afv141

7. Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M et al. 2018 ESC/ESH Guidelines for the man agement of arterial hypertension. European Heart Journal. 2018;39(33):3021–104. DOI: 10.1093/eurheartj/ehy339

8. Messerli FH, Bangalore S, Bavishi C, Rimoldi SF. AngiotensinConverting Enzyme Inhibitors in Hypertension. Journal of the American College of Cardiology. 2018;71(13):1474–82. DOI: 10.1016/j.jacc.2018.01.058

9. Conlin PR, Gerth WC, Fox J, Roehm JB, Boccuzzi SJ. Four-year persistence patterns among patients initiating therapy with the angiotensin II receptor antagonist losartan versus other antihypertensive drug classes. Clinical Therapeutics. 2001;23(12):1999–2010. DOI: 10.1016/S0149-2918(01)80152-1

10. Морозова Т.Е. Сартаны в лечении больных артериальной гипертензией высокого риска: возможности кандесартана. Системные гипертензии. 2013;10(2):13–8

11. Sever P, Holzgreve H. Long-term efficacy and tolerability of candesartan cilexetil in patients with mild to moderate hypertension. Journal of Human Hypertension. 1997;11(Suppl 2):S69-73. PMID: 9331014

12. McInnes GT, O’Kane KP, Jonker J, Roth J. The efficacy and tolerability of candesartan cilexetil in an elderly hypertensive population. Journal of Human Hypertension. 1997;11(Suppl 2):S75-80. PMID: 9331015

13. Belcher G, Hübner R, George M, Elmfeldt D, Lunde H. Candesartan cilexetil: safety and tolerability in healthy volunteers and patients with hypertension. Journal of Human Hypertension. 1997;11(Suppl 2):S85-89. PMID: 9331017

14. Trenkwalder P. Efficacy and tolerability of candesartan cilexetil in special patient groups. Blood Pressure. Supplement. 2000;1:27–30. PMID: 11059633

15. Andersson OK, Neldam S. The antihypertensive effect and tolerability of candesartan cilexetil, a new generation angiotensin II antagonist, in comparison with losartan. Blood Pressure. 1998;7(1):53–9. PMID: 9551878

16. Bakris GL, Gilles TD, Weber MA. Clinical efficacy and safety profiles of AT1-receptor antagonists. Cardiovascular Reviews & Reports. 1999;20(2):77–100

17. Bakris G, Gradman A, Reif M, Wofford M, Munger M, Harris S et al. Antihypertensive Efficacy of Candesartan in Comparison to Losartan: The CLAIM Study. The Journal of Clinical Hypertension. 2001;3(1):16–21. DOI: 10.1111/j.1524-6175.2001.00826.x

18. Cuspidi C, Muiesan ML, Valagussa L, Salvetti M, Di Biagio C, AgabitiRosei E et al. Comparative effects of candesartan and enalapril on left ventricular hypertrophy in patients with essential hypertension: the candesartan assessment in the treatment of cardiac hypertrophy (CATCH) study. Journal of Hypertension. 2002;20(11):2293–300. DOI: 10.1097/00004872-200211000-00030

19. Hadi NR, Yousif NG, Abdulzahra MS, Mohammad BI, al-amran FG, Majeed ML et al. Role of NF-κβ and Oxidative Pathways in Atherosclerosis: Cross-Talk Between Dyslipidemia and Candesartan. Cardiovascular Therapeutics. 2013;31(6):381–7. DOI: 10.1111/1755-5922.12033

20. Lindholm LH, Persson M, Alaupovic P, Carlberg B, Svensson A, Samuelsson O. Metabolic outcome during 1 year in newly detected hypertensives: results of the Antihypertensive Treatment and Lipid Profile in a North of Sweden Efficacy Evaluation (ALPINE study). Journal of Hypertension. 2003;21(8):1563–74. DOI: 10.1097/01.hjh.0000084723.53355.76

21. Yusuf S, Ostergren JB, Gerstein HC, Pfeffer MA, Swedberg K, Granger CB et al. Effects of Candesartan on the Development of a New Diagnosis of Diabetes Mellitus in Patients With Heart Failure. Circulation. 2005;112(1):48–53. DOI: 10.1161/CIRCULATIONAHA.104.528166

22. Lithell H, Hansson L, Skoog I, Elmfeldt D, Hofman A, Olofsson B et al. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. Journal of Hypertension. 2003;21(5):875–86. DOI: 10.1097/01.hjh.0000059028.82022.89

23. Skoog I, Lithell H, Hansson L, Elmfeldt D, Hofman A, Olofsson B et al. Effect of Baseline Cognitive Function and Antihypertensive Treatment on Cognitive and Cardiovascular Outcomes: Study on COgnition and Prognosis in the Elderly (SCOPE). American Journal of Hypertension. 2005;18(8):1052–9. DOI: 10.1016/j.amjhyper.2005.02.013

24. Ткачева О.Н., Рунихина Н.К., Шарашкина Н.В. Торасемид: дополнительные преимущества применения при артериальной гипертензии у женщин в постменопаузе. Системные гипертензии. 2013;10(2):9–13

25. Friedel HA, Buckley MM-T. Torasemide: A Review of its Pharmacological Properties and Therapeutic Potential. Drugs. 1991;41(1):81–103. DOI: 10.2165/00003495-199141010-00008

26. López B, González A, Beaumont J, Querejeta R, Larman M, Díez J. Identification of a Potential Cardiac Antifibrotic Mechanism of Torasemide in Patients With Chronic Heart Failure. Journal of the American College of Cardiology. 2007;50(9):859–67. DOI: 10.1016/j.jacc.2007.04.080

27. Орлова Я.А., Ткачева О.Н., Арутюнов Г.П., Котовская Ю.В., Лопатин Ю.М., Мареев В.Ю. и др. Особенности диагностики и лечения хронической сердечной недостаточности у пациентов пожилого и старческого возраста. Мнение экспертов общества специалистов по сердечной недостаточности, российской ассоциации геронтологов и гериатров и евразийской ассоциации терапевтов. Кардиология. 2018;58(S12):42–72. DOI: 10.18087/cardio.2560

28. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. European Heart Journal. 2016;37(27):2129–200. DOI: 10.1093/eurheartj/ehw128

29. McMurray JJ, Östergren J, Swedberg K, Granger CB, Held P, Michelson EL et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. The Lancet. 2003;362(9386):767–71. DOI: 10.1016/S0140-6736(03)14283-3

30. Granger CB, McMurray JJ, Yusuf S, Held P, Michelson EL, Olofsson B et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARMAlternative trial. The Lancet. 2003;362(9386):772–6. DOI: 10.1016/S0140-6736(03)14284-5

31. Мареев В.Ю., Фомин И.В., Агеев Ф.Т., Арутюнов Г.П., Беграмбекова Ю.Л., Беленков Ю.Н. и др. Клинические рекомендации. Хроническая сердечная недостаточность (ХСН). Журнал Сердечная Недостаточность. 2017;18(1):3–40. DOI: 10.18087/rhfj.2017.1.2346

32. Yusuf S, Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. The Lancet. 2003;362(9386):777–81. DOI: 10.1016/S0140-6736(03)14285-7

33. Law M, Wald N, Morris J. Lowering blood pressure to prevent myocardial infarction and stroke: a new preventive strategy. Health Technology Assessment (Winchester, England). 2003;7(31):1–94. PMID: 14604498

34. Müller K, Gamba G, Jaquet F, Hess B. Torasemide vs. furosemide in primary care patients with chronic heart failure NYHA II to IV-efficacy and quality of life. European Journal of Heart Failure. 2003;5(6):793–801. DOI: 10.1016/S1388-9842(03)00150-8

35. Ozieranski K, Balsam P, Kaplon-Cieslicka A, Tyminska A, Kowalik R, Grabowski M et al. P5281Comparison of long-term outcomes of torasemide vs furosemide in heart failure patients. results from Heart Failure Registries of the European Society of Cardiology. European Heart Journal. 2017;38(Suppl 1):1107–8. DOI: 10.1093/eurheartj/ehx493.P5281

36. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet (London, England). 1994;344(8934):1383–9. PMID: 7968073

37. LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart J-C et al. Intensive Lipid Lowering with Atorvastatin in Patients with Stable Coronary Disease. New England Journal of Medicine. 2005;352(14):1425–35. DOI: 10.1056/NEJMoa050461

38. Catapano AL, Graham I, De Backer G, Wiklund O, Chapman MJ, Drexel H et al. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. European Heart Journal. 2016;37(39):2999–3058. DOI: 10.1093/eurheartj/ehw272

39. Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NL A/PCNA Guideline on the Management of Blood Cholesterol: Executive Summary. Journal of the American College of Cardiology. 2019;73(24):3168–209. DOI: 10.1016/j.jacc.2018.11.002

40. Schuster H. The GALAXY Program: an update on studies investigating efficacy and tolerability of rosuvastatin for reducing cardiovascular risk. Expert Review of Cardiovascular Therapy. 2007;5(2):177–93. DOI: 10.1586/14779072.5.2.177

41. Comprehensive management of high risk cardiovascular patients. Gotto AM, Toth PP, editors -New York: Informa Healthcare;2007. -770 p. ISBN 978-0-8493-4066-6

42. Larson EB. Adverse Drug Reactions Associated with Global Cognitive Impairment in Elderly Persons. Annals of Internal Medicine. 1987;107(2):169–73. DOI: 10.7326/0003-4819-107-2-169

43. Ogu CC, Maxa JL. Drug Interactions Due to Cytochrome P450. Baylor University Medical Center Proceedings. 2000;13(4):421–3. DOI: 10.1080/08998280.2000.11927719

44. Гилман А.Г. Клиническая фармакология по Гудману и Гилману. – М.: Практика, 2006. – 448 с. ISBN 5-89816-067-1

45. Hasler JA. Pharmacogenetics of cytochromes P450. Molecular Aspects of Medicine. 1999;20(1–2):12–137. PMID: 10575648

46. Sirtori CR. The pharmacology of statins. Pharmacological Research. 2014;88:3–11. DOI: 10.1016/j.phrs.2014.03.002

47. DeGorter MK, Tirona RG, Schwarz UI, Choi Y-H, Dresser GK, Suskin N et al. Clinical and Pharmacogenetic Predictors of Circulating Atorvastatin and Rosuvastatin Concentrations in Routine Clinical Care. Circulation: Cardiovascular Genetics. 2013;6(4):400–8. DOI: 10.1161/CIRCGENETICS.113.000099

48. Vauquelin G, Szczuka A. Kinetic versus allosteric mechanisms to explain insurmountable antagonism and delayed ligand dissociation. Neurochemistry International. 2007;51(5):254–60. DOI: 10.1016/j.neuint.2007.05.005

49. Zou Y, Akazawa H, Qin Y, Sano M, Takano H, Minamino T et al. Mechanical stress activates angiotensin II type 1 receptor without the involvement of angiotensin II. Nature Cell Biology. 2004;6(6):499–506. DOI: 10.1038/ncb1137

50. Milligan G. Constitutive Activity and Inverse Agonists of G Protein-Coupled Receptors: a Current Perspective. Molecular Pharmacology. 2003;64(6):1271–6. DOI: 10.1124/mol.64.6.1271

51. Iekushi K, Taniyama Y, Azuma J, Katsuragi N, Dosaka N, Sanada F et al. Novel Mechanisms of Valsartan on the Treatment of Acute Myocardial Infarction Through Inhibition of the Antiadhesion Molecule Periostin. Hypertension. 2007;49(6):1409–14. DOI: 10.1161/HYPERTENSIONAHA.106.080994

52. Lacourcière Y, Asmar R. A comparison of the efficacy and duration of action of candesartan cilexetil and losartan as assessed by clinic and ambulatory blood pressure after a missed dose, in truly hypertensive patients: a placebo-controlled, forced titration study. Candesartan/Losartan study investigators. American Journal of Hypertension. 1999;12(12 Pt 1-2):1181–7. PMID: 10619580